Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Bioscience Investing

  • Featured Story

    Test-tubes-biotech-chemistry

    Medical device companies can be profit-making machines - one manufacturer of magnetic resonance imaging (MRI) machines and other high-tech products is up more than 250% over the past 12 months, for instance.

    Most of them make their living by staying on the leading edge of innovation, producing some of the coolest gadgets you can imagine.

    And, even better, they can deliver some of the most impressive gains in the bioscience industry to their shareholders.

    The good performance of these manufacturers gives you some idea of the potential we're dealing with here.

    Just look at these soaring share prices...

Article Index

Ebola Stocks Surge as Race for Treatment Heats Up – but Steer Clear of Overhyped Plays

Ebola Stocks

The number of companies racing to find an Ebola treatment is increasing. All drugs remain in the testing stage, but that hasn't stopped investors from piling into these "Ebola stocks."

Chimerix (Nasdaq: CMRX) climbed 5% Monday on reports that the Ebola patient in Dallas is being treated with its drug, brincidofovir.

Read More…

These Biotech Stocks Are Tied to the World’s Most Expensive New Drugs

biotech stocks

One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.

Here are a closer look at the priciest drugs – and the biotech stocks behind them…

A Clear Way to Profit from a Graying Population

The Baby Boom generation, which includes everyone born from 1946 through 1964, is now entering retirement age (65) at a rate of 10,000 per day. That demographic wave is so big that in 2010, the U.S. Administration on Aging (AoA) predicted the elderly population in this country would double to about 71 million by 2030.

That presents a huge opportunity for bioscience investors. Here's why.